Salt AI, a specialist in contextual artificial intelligence at Life Sciences and Health Tech Industries, has announced a $10 million funding round. The investment was led by Morpheus Ventures and received additional support from Struck Capital, Marbruck Investments and CoreWeave.
This funding will help Salt AI grow its customer base among biopharmaceuticals and healthcare institutions that are actively investing in advanced AI technologies. It also allows the company to expand its global engineering team, thereby accelerating development and increasing the impact of the platform.
Salt AI's platform is designed to make enterprise AI more transparent and accessible. Many organizations suffer from the complexity and opacity of traditional AI systems, often referred to as “black boxes.” SALT AI addresses this by providing a visual first interface that supports full coding capabilities. This allows teams to build, deploy and manage AI-powered workflows across a variety of business functions. From drug discovery and clinical trials to revenue cycle management and data navigation.
One example of the impact of Salt AI can be seen at the Ellison Medical Institute, where the platform is used to accelerate research in computational biology. Since mid-2024, EMI has been using salt AI to design and analyze thousands of compounds, leading to more in-depth laboratory studies of two promising protein candidates. The flexible workflow of the platform makes it easier for researchers to move from concept to experiment by continuously improving their digital design processes.
At the heart of Salt AI's technology is Salt Matrix, a catalog of specialized data connectors, models and tools tailored to the needs of Life Sciences and Healthcare teams. Users can quickly build AI workflows using drag and drop functionality. This simplifies collaboration between scientists, engineers and business leaders. The platform is built around three core strengths. Enable real-time collaboration between disciplines, deliver fast results through rapid deployment in private or on-premises environments, and maintain strict compliance standards for enterprise-level adoption.
With this new funding, Salt AI is deepening its role in transforming the way healthcare and biotech companies use AI, allowing them to unlock faster innovation and more efficient operations across the board.
Important Quotes:
“SALT AI is intended to support CoreWeave, which aims to apply AI to one of the most urgent challenges in society. The AI cloud platform is dedicated to complex models, allowing Salt AI to run workloads quickly and reliably, providing life science companies with a practical way to integrate AI into everyday research.”
Brian Venturo, CoreWeave, Co-Founder and Chief Strategy Officer
“We are in the midst of a life science breakthrough moment, and AI is igniting unprecedented opportunities that have once been out of reach. A single AI model cannot unleash the future of medicine. America reaches new milestones with discoveries and improves real-world outcomes across the industry.”
Aber Whitcomb, CEO and co-founder of Salt AI
“SALT AI represents a transformative advancement in the computational biology stack. By combining drag and drop workflows with transparent AI integration, the platform enables new, faster, more efficient, and data-driven paradigms.”
Dr. David Agus, founder of CEO of Ellison Medical Institute.
